Moreover, the combination of sorafenib and everolimus, an inhibitor of mammalian target of rapamycin (mTOR), enhanced antiproliferative, proapoptotic and antiangiogenic effects, reducing tumor growth and its propensity to metastasize in OS mice model8. Here, MTOR is linked to neoplasm.